EP3908583 - DOT1L DEGRADERS AND USES THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 15.10.2021 Database last updated on 21.05.2024 | |
Former | The international publication has been made Status updated on 18.07.2020 | Most recent event Tooltip | 29.01.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Dana-Farber Cancer Institute, Inc. 450 Brookline Avenue Boston, MA 02215 / US | [2021/46] | Inventor(s) | 01 /
ARMSTRONG, Scott 233 Rice Road Wayland, MA 01778 / US | 02 /
QI, Jun 26 Pine Grove Avenue Sharon, MA 02067 / US | [N/P] |
Former [2021/46] | 01 /
ARMSTRONG, Scott Wayland, MA 01778 / US | ||
02 /
QI, Jun Sharon, MA 02067 / US | Representative(s) | Haseltine Lake Kempner LLP Cheapside House 138 Cheapside London EC2V 6BJ / GB | [2021/46] | Application number, filing date | 20739213.5 | 09.01.2020 | [2021/46] | WO2020US12825 | Priority number, date | US201962790314P | 09.01.2019 Original published format: US 201962790314 P | [2021/46] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020146561 | Date: | 16.07.2020 | Language: | EN | [2020/29] | Type: | A1 Application with search report | No.: | EP3908583 | Date: | 17.11.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 16.07.2020 takes the place of the publication of the European patent application. | [2021/46] | Search report(s) | International search report - published on: | US | 16.07.2020 | (Supplementary) European search report - dispatched on: | EP | 08.07.2022 | Classification | IPC: | C07H19/167, A61P35/00 | [2022/32] | CPC: |
C07H19/167 (EP);
C07H19/16 (US);
A61P35/00 (EP);
A61P35/02 (US)
|
Former IPC [2021/46] | C07D401/14, C07D471/04, C07D487/04 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/46] | Title | German: | DOT1L-DEGRADER UND VERWENDUNGEN DAVON | [2021/46] | English: | DOT1L DEGRADERS AND USES THEREOF | [2021/46] | French: | AGENTS DE DÉGRADATION DE DOT1L ET UTILISATIONS ASSOCIÉES | [2021/46] | Entry into regional phase | 27.06.2021 | National basic fee paid | 27.06.2021 | Search fee paid | 27.06.2021 | Designation fee(s) paid | 27.06.2021 | Examination fee paid | Examination procedure | 27.06.2021 | Examination requested [2021/46] | 05.02.2023 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 27.01.2022 | Renewal fee patent year 03 | 27.01.2023 | Renewal fee patent year 04 | 29.01.2024 | Renewal fee patent year 05 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO2014153001 (EPIZYME INC [US]) [A] 1-15 * the whole document *; | [AP]WO2020006157 (DANA FARBER CANCER INST INC [US]) [AP] 1-15* the whole document * | International search | [Y]US2016106725 (RODEN RICHARD B [US], et al) [Y] 1-3, 34 * , entire document, especially: abstract; para [0007]; pg 26, Table 7, formula RA190F; para [0155]; para [0153]. *; | [A]US2017232030 (KLAUS CHRISTINE [US], et al) [A] 1-3, 34* , entire document. *; | [Y] - KLAUS et al., "DOT1 L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs and Hypomethylating Agents in MLL-Rearranged Leukemia Cells", J Pharmacol Exp Ther., (20140000), vol. 350, doi:10.1124/jpet.114.214577, pages 646 - 656, XP055292901 [Y] 1-3,34 * , entire document, especially: abstract, EPZ-5676. * DOI: http://dx.doi.org/10.1124/jpet.114.214577 | [A] - PubChem, (20120709), Database accession no. 57345410, XP055724863 [A] 1-3, 34 * , pg 2, Fig. * | by applicant | WO2014153001 | US2016058872 | US2016060269 | US2016106725 | US9694084 | US9913834 | - WILEN et al., Tetrahedron, (19770000), vol. 33, page 2725 | - WILEN, Tables of Resolving Agents and Optical Resolutions, Univ. of Notre Dame Press, (19720000), page 268 | - BERGE et al., J. Pharmaceutical Sciences, (19770000), vol. 66, pages 501 - 502 | - BUNDGARD, H., Design of Prodrugs, Elsevier, (19850000), vol. 21-24, pages 7 - 9 |